| 词条 | Lucinactant |
| 释义 |
| type = combo | component1 = Sinapultide | class1 = | component2 = Dipalmitoylphosphatidylcholine | class2 = | component3 = 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol | class3 = | component4 = palmitic acid | class4 = | tradename = Surfaxin | Drugs.com = | MedlinePlus = | pregnancy_AU = | pregnancy_US = | pregnancy_category= | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = | CAS_number = 825600-90-6 | ATCvet = | ATC_prefix = R07 | ATC_suffix = AA30 | PubChem = | DrugBank = }}Lucinactant (trade name Surfaxin) is a liquid medication used to treat infant respiratory distress syndrome.[1] It is a pulmonary surfactant for infants who lack enough natural surfactant in their lungs. Whereas earlier medicines of the class, such as beractant (Survanta & Beraksurf), calfactant (Infasurf), and poractant (Curosurf), are derived from animals, lucinactant is synthetic. It was approved for use in the United States by the U.S. Food and Drug Administration (FDA) on March 6, 2012.[2] Medical usesLucinactant is indicated to improve lung function and reduce duration and risk of mechanical ventilation in children. It can be used up to two years of age and is specified for children who are diagnosed with acute respiratory failure following exposure to a pathogen such as RSV or influenza, including H1N1.[3][4][5] Lucinactant is also used to treat meconium aspiration syndrome.[5][6] ChemistryLucinactant contains the peptide sinapultide (KL4 acetate), dipalmitoylphosphatidylcholine (DPPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol (POPG, as the sodium salt), and palmitic acid. HistoryThe scientific groundwork for lucinactant was laid in the laboratory of Charles Cochrane at The Scripps Research Institute in the 1990s.[7] The drug was then developed by Discovery Laboratories of Warrington, PA. The path through the approval process was unusually long, reflecting in part challenges in the manufacturing process that needed to be addressed before approval was granted.[8] Legal statusLucinactant is listed as an Orphan Drug Product by the US Food and Drug Administration for several conditions:[9][10]
Clinical trials in Latin America were criticized for protocol based in potentially unethical principles.[11] A placebo was used and considered ethical by design since infants born in Latin America usually do not have access to life saving treatment. The intent of Discovery Labs was always to market Surfaxin in the United States, implying burdens on the Latin American children that outweighed the benefits. References1. ^ {{webarchive |url=https://web.archive.org/web/20090420135625/http://www.discoverylabs.com/surfaxin.html |date=April 20, 2009 }} 2. ^{{cite web|url=http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm294984.htm |title=FDA approves Surfaxin to prevent breathing disorder in premature infants |publisher=Fda.gov |date=2012-03-06 |accessdate=2012-10-20}} 3. ^{{cite news|url=http://money.cnn.com/news/newsfeeds/articles/globenewswire/182115.htm |deadurl=yes |archiveurl=https://web.archive.org/web/20100122205312/http://money.cnn.com/news/newsfeeds/articles/globenewswire/182115.htm |archivedate=January 22, 2010 }} 4. ^{{Cite journal| doi = 10.1164/ajrccm.160.4.9808118| pmid = 10508806| year = 1999| last1 = Wiswell | first1 = T. E.| last2 = Smith | first2 = R. M.| last3 = Katz | first3 = L. B.| last4 = Mastroianni | first4 = L.| last5 = Wong | first5 = D. Y.| last6 = Willms | first6 = D.| last7 = Heard | first7 = S.| last8 = Wilson | first8 = M.| last9 = Hite | first9 = R. D.| last10 = Anzueto | first10 = A.| last11 = Revak | first11 = S. D.| last12 = Cochrane | first12 = C. G.| title = Bronchopulmonary segmental lavage with Surfaxin (KL(4)-surfactant) for acute respiratory distress syndrome| volume = 160| issue = 4| pages = 1188–1195| journal = American Journal of Respiratory and Critical Care Medicine}} 5. ^1 {{Cite journal| doi = 10.1517/13543784.14.3.329| pmid = 15833063| year = 2005| last1 = Donn | first1 = S.| title = Lucinactant: a novel synthetic surfactant for the treatment of respiratory distress syndrome| volume = 14| issue = 3| pages = 329–334| journal = Expert Opinion on Investigational Drugs }} 6. ^{{Cite journal| pmid = 12042546| year = 2002| last1 = Wiswell | first1 = T. E.| last2 = Knight | first2 = G. R.| last3 = Finer | first3 = N. N.| last4 = Donn | first4 = S. M.| last5 = Desai | first5 = H.| last6 = Walsh | first6 = W. F.| last7 = Sekar | first7 = K. C.| last8 = Bernstein | first8 = G.| last9 = Keszler | first9 = M.| last10 = Visser | first10 = V. E.| last11 = Merritt | first11 = T. A.| last12 = Mannino | first12 = F. L.| last13 = Mastrioianni | first13 = L.| last14 = Marcy | first14 = B.| last15 = Revak | first15 = S. D.| last16 = Tsai | first16 = H.| last17 = Cochrane | first17 = C. G.| title = A multicenter, randomized, controlled trial comparing Surfaxin (Lucinactant) lavage with standard care for treatment of meconium aspiration syndrome| volume = 109| issue = 6| pages = 1081–1087| journal = Pediatrics| doi = 10.1542/peds.109.6.1081}} 7. ^{{cite web|url=http://www.scripps.edu/news/press/20120306cochrane.html |title=Scripps Research Discoveries Lead to Newly Approved Drug for Infant Respiratory Distress Syndrome |publisher=Scripps.edu |date=2012-03-06 |accessdate=2012-10-20}} 8. ^{{cite web|url=http://www.pharmacychoice.com/news/article.cfm?Article_ID=854519 |title=Pharmaceutical News - Discovery Labs Turns Focus To Surfaxin Market Strategy - October 20, 2012 |publisher=Pharmacy Choice |date= |accessdate=2012-10-20}} 9. ^{{cite web|url=http://google2.fda.gov/search?q=cache:LCsiKMwG2v0J:www.fda.gov/ohrms/dockets/dailys/00/mar00/030100/lst0094.pdf+surfaxin&client=FDAgov&site=FDAgov&lr=&proxystylesheet=FDAgov&output=xml_no_dtd&ie=UTF-8&access=p&oe=UTF-8 |title=List Of Orphan Products Designations And Approvals |publisher=Google2.fda.gov |date= |accessdate=2012-10-20}} 10. ^{{cite web|url=http://www.nelm.nhs.uk/en/NeLM-Area/News/485098/485446/485460/ |title=Page expired |publisher=Nelm.nhs.uk |date= |accessdate=2012-10-20}} 11. ^{{cite journal|last=Charatan|first=Fred|title=Surfactant trial in Latin American infants criticised|journal=BMJ|date=10 March 2001|volume=322|series=7286|page=575|pmc=1119782|pmid=11238147|doi=10.1136/bmj.322.7286.575/b}} 3 : Drugs acting on the respiratory system|Pediatrics|Respiratory and cardiovascular disorders specific to the perinatal period |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。